Is ALMS or SLDB more profitable?

Solid Biosciences has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Solid Biosciences' return on equity of -73.42% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% Solid Biosciences N/A -73.42% -61.13%

Does the media prefer ALMS or SLDB?

In the previous week, Solid Biosciences had 2 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Alumis. Alumis' average media sentiment score of 1.45 beat Solid Biosciences' score of 0.72 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, IRON or SLDB?

Disc Medicine is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.62 N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is IRON or SLDB more profitable?

Disc Medicine's return on equity of -36.94% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -36.94% -33.88% Solid Biosciences N/A -73.42% -61.13%

Does the media favor IRON or SLDB?

In the previous week, Disc Medicine had 5 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for Disc Medicine and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.72 beat Disc Medicine's score of 0.44 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARQT or SLDB?

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 4 mentions for Solid Biosciences. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Solid Biosciences' score of 0.72 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SLDB or TARS?

In the previous week, Solid Biosciences and Solid Biosciences both had 4 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 0.73 beat Solid Biosciences' score of 0.72 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IDYA or SLDB more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Solid Biosciences N/A -73.42% -61.13%

Does the media prefer IDYA or SLDB?

In the previous week, IDEAYA Biosciences had 3 more articles in the media than Solid Biosciences. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.72 beat IDEAYA Biosciences' score of 0.11 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Solid Biosciences (SLDB) Competitors

$6.85 +0.27 (+4.10%)

Closing price 04:00 PM Eastern

Extended Trading

$6.75 -0.10 (-1.50%)

As of 07:58 PM Eastern

Compare

SLDB vs. ALMS, IRON, ARQT, TARS, and IDYA

Should you buy Solid Biosciences stock or one of its competitors? MarketBeat compares Solid Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solid Biosciences include Alumis (ALMS), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry.

How does Solid Biosciences compare to Alumis?

Alumis (NASDAQ:ALMS) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Alumis currently has a consensus target price of $40.30, indicating a potential upside of 100.70%. Solid Biosciences has a consensus target price of $16.82, indicating a potential upside of 145.52%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Solid Biosciences has lower revenue, but higher earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	106.44	-$243.32M	-$1.98	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

81.5% of Solid Biosciences shares are owned by institutional investors. 33.7% of Alumis shares are owned by insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Solid Biosciences had 2 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Alumis. Alumis' average media sentiment score of 1.45 beat Solid Biosciences' score of 0.72 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alumis has a beta of -0.56, meaning that its share price is 156% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Solid Biosciences' return on equity of -73.42% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Solid Biosciences	N/A	-73.42%	-61.13%

Summary

Solid Biosciences beats Alumis on 12 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Disc Medicine has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

Disc Medicine's return on equity of -36.94% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Solid Biosciences	N/A	-73.42%	-61.13%

Disc Medicine currently has a consensus price target of $105.30, indicating a potential upside of 49.68%. Solid Biosciences has a consensus price target of $16.82, indicating a potential upside of 145.52%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Disc Medicine is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 3.8% of Disc Medicine shares are held by insiders. Comparatively, 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Disc Medicine had 5 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for Disc Medicine and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.72 beat Disc Medicine's score of 0.44 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solid Biosciences beats Disc Medicine on 9 of the 14 factors compared between the two stocks.

How does Solid Biosciences compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

81.5% of Solid Biosciences shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 4 mentions for Solid Biosciences. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Solid Biosciences' score of 0.72 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has higher revenue and earnings than Solid Biosciences. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.10	-$16.14M	-$0.03	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Arcutis Biotherapeutics presently has a consensus target price of $34.00, suggesting a potential upside of 59.25%. Solid Biosciences has a consensus target price of $16.82, suggesting a potential upside of 145.52%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Solid Biosciences has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Solid Biosciences	N/A	-73.42%	-61.13%

Arcutis Biotherapeutics has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market.

Summary

Arcutis Biotherapeutics and Solid Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Solid Biosciences compare to Tarsus Pharmaceuticals?

Solid Biosciences (NASDAQ:SLDB) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Solid Biosciences currently has a consensus target price of $16.82, indicating a potential upside of 145.52%. Tarsus Pharmaceuticals has a consensus target price of $90.67, indicating a potential upside of 54.30%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Solid Biosciences is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

In the previous week, Solid Biosciences and Solid Biosciences both had 4 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 0.73 beat Solid Biosciences' score of 0.72 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Tarsus Pharmaceuticals has higher revenue and earnings than Solid Biosciences. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Tarsus Pharmaceuticals	$451.36M	5.60	-$66.42M	-$1.14	N/A

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats Solid Biosciences on 9 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

IDEAYA Biosciences' return on equity of -14.24% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Solid Biosciences	N/A	-73.42%	-61.13%

IDEAYA Biosciences currently has a consensus target price of $50.69, suggesting a potential upside of 78.48%. Solid Biosciences has a consensus target price of $16.82, suggesting a potential upside of 145.52%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Solid Biosciences is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 2.7% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

IDEAYA Biosciences has higher revenue and earnings than Solid Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	11.41	-$113.70M	-$1.60	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

In the previous week, IDEAYA Biosciences had 3 more articles in the media than Solid Biosciences. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.72 beat IDEAYA Biosciences' score of 0.11 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market.

Summary

IDEAYA Biosciences beats Solid Biosciences on 9 of the 15 factors compared between the two stocks.

Get Solid Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLDB vs. The Competition

Export

Metric	Solid Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$647.80M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-3.51	17.78	22.39	24.18
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	3.00	6.63	9.84	6.72
Net Income	-$174.32M	$24.20M	$3.57B	$337.19M
7 Day Performance	-2.42%	-3.24%	-1.16%	0.48%
1 Month Performance	-3.93%	0.53%	3.85%	5.07%
1 Year Performance	95.71%	47.24%	27.40%	34.25%

Solid Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLDB Solid Biosciences	2.7909 of 5 stars	$6.85 +4.1%	$16.82 +145.5%	+85.9%	$647.80M	N/A	N/A	100	Analyst Forecast Gap Up
ALMS Alumis	2.9407 of 5 stars	$21.40 +0.3%	$40.30 +88.3%	+509.1%	$2.72B	$24.05M	N/A	N/A	Positive News
IRON Disc Medicine	1.928 of 5 stars	$70.80 +1.5%	$105.30 +48.7%	+42.5%	$2.66B	N/A	N/A	30	News Coverage
ARQT Arcutis Biotherapeutics	3.3506 of 5 stars	$21.44 +1.4%	$34.00 +58.6%	+54.2%	$2.65B	$376.07M	N/A	150	Positive News
TARS Tarsus Pharmaceuticals	2.8335 of 5 stars	$59.54 -0.9%	$90.67 +52.3%	+30.9%	$2.58B	$451.36M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLDB) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solid Biosciences (SLDB) Competitors

SLDB vs. ALMS, IRON, ARQT, TARS, and IDYA

How does Solid Biosciences compare to Alumis?

Summary

How does Solid Biosciences compare to Disc Medicine?

Summary

How does Solid Biosciences compare to Arcutis Biotherapeutics?

Summary

How does Solid Biosciences compare to Tarsus Pharmaceuticals?

Summary

How does Solid Biosciences compare to IDEAYA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solid Biosciences (SLDB) Competitors

SLDB vs. ALMS, IRON, ARQT, TARS, and IDYA

How does Solid Biosciences compare to Alumis?

Do analysts prefer ALMS or SLDB?

Which has preferable earnings & valuation, ALMS or SLDB?

Do institutionals and insiders believe in ALMS or SLDB?

Does the media prefer ALMS or SLDB?

Which has more risk and volatility, ALMS or SLDB?

Is ALMS or SLDB more profitable?

Summary

How does Solid Biosciences compare to Disc Medicine?

Which has more volatility & risk, IRON or SLDB?

Is IRON or SLDB more profitable?

Do analysts rate IRON or SLDB?

Which has better valuation and earnings, IRON or SLDB?

Do institutionals & insiders have more ownership in IRON or SLDB?

Does the media favor IRON or SLDB?

Summary

How does Solid Biosciences compare to Arcutis Biotherapeutics?

Do institutionals and insiders hold more shares of ARQT or SLDB?

Does the media favor ARQT or SLDB?

Which has higher valuation and earnings, ARQT or SLDB?

Do analysts recommend ARQT or SLDB?

Is ARQT or SLDB more profitable?

Which has more risk & volatility, ARQT or SLDB?

Summary

How does Solid Biosciences compare to Tarsus Pharmaceuticals?

Do analysts prefer SLDB or TARS?

Does the media refer more to SLDB or TARS?

Which has more volatility and risk, SLDB or TARS?

Is SLDB or TARS more profitable?

Which has better valuation & earnings, SLDB or TARS?

Do institutionals & insiders have more ownership in SLDB or TARS?

Summary

How does Solid Biosciences compare to IDEAYA Biosciences?

Is IDYA or SLDB more profitable?

Do analysts rate IDYA or SLDB?

Do institutionals & insiders believe in IDYA or SLDB?

Which has stronger earnings and valuation, IDYA or SLDB?

Does the media prefer IDYA or SLDB?

Which has more volatility and risk, IDYA or SLDB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools